Michael Brigham‐Burke

Author

Also Known As

M BRIGHAM-BURKE, M. Brigham-Burke, M. Brighamburke, M.R. Brigham-Burke, Michael BRIGHAM-BURKE, Michael Brigham-Burke, Michael Brigham‐Burke, Michael R Brigham-Burke, Michael R. Brigham-Burke

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

New Frontier CSL (United States)Protein Express (United States)GlaxoSmithKline (United States)Molecular Biology Consortium

About

Michael Brigham‐Burke is an author at New Frontier specializing in medicine, immunology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.4K
2	Biochemistry	8	8	390
3	Engineering	7	7	1.2K
4	Natural Sciences	6	6	530
5	Allergy	2	2	229

Michael Brigham‐Burke

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Determination of Rate and Equilibrium Binding Constants for Macromolecular Interactions Using Surface Plasmon Resonance: Use of Nonlinear Least Squares Analysis Methods Daniel J. O’Shannessy, Michael Brigham‐Burke, K. Karl Soneson, Analytical Biochemistry EngineeringPhysical ChemistryComputational ChemistryMolecular SimulationChemistry	1993	547
Energetics of the HIV gp120-CD4 binding reaction David G. Myszka, Raymond W. Sweet, Preston Hensley, Proceedings of the National Academy of Sciences Virus StructureProtein AssemblyProtein FoldingNatural SciencesMedicine	2000	418
INTERLEUKIN-1F7B (IL-1H4/IL-1F7) IS PROCESSED BY CASPASE-1 AND MATURE IL-1F7B BINDS TO THE IL-18 RECEPTOR BUT DOES NOT INDUCE IFN-γ PRODUCTION Sanjay Kumar, Charles R. Hanning, Michael Brigham‐Burke, Cytokine InflammationCytokineImmune Cell DevelopmentImmune RegulationImmunology	2002	254
Immobilization chemistries suitable for use in the BIAcore surface plasmon resonance detector Daniel J. O’Shannessy, Michael Brigham‐Burke, Kim Peck Analytical Biochemistry Immobilization ChemistriesPlasmonicsChemical EngineeringEngineeringBiomedical Diagnostics	1992	246
Herpesvirus Entry Mediator Ligand (HVEM-L), a Novel Ligand for HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth Jeremy Harrop, Peter McDonnell, Michael Brigham‐Burke, Journal of Biological Chemistry	1998	240
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma T K Hart, M N Blackburn, Michael Brigham‐Burke, Clinical & Experimental Immunology AsthmaClinical ImmunologyInflammatory Lung DiseaseImmunologyImmune Regulation	2002	200
Phospholipid/Alkanethiol Bilayers for Cell-Surface Receptor Studies by Surface Plasmon Resonance Anne L. Plant, Michael Brigham‐Burke, Eugene C. Petrella, Analytical Biochemistry Proteinlipid InteractionEngineeringBiochemistryBiomedical DiagnosticsBiosensing Systems	1995	186
Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4 Manjula Reddy, Cheryl Ann S. Kinney, Margery A. Chaikin, The Journal of Immunology	2000	131
Antibodies to TR2 (Herpesvirus Entry Mediator), a New Member of the TNF Receptor Superfamily, Block T Cell Proliferation, Expression of Activation Markers, and Production of Cytokines Jeremy Harrop, Manjula Reddy, Kimberly Dede, The Journal of Immunology T-regulatory CellViral PathogenesisImmunologyRegulatory T CellsTnf Receptor Superfamily	1998	127
Detection of receptor-ligand interactions using surface plasmon resonance: Model studies employing the HIV-1 gp120/CD4 interaction Michael Brigham‐Burke, John Edwards, Daniel J. O’Shannessy Analytical Biochemistry PlasmonicsEngineeringMedicineMolecular BiologyReceptor-ligand Interactions	1992	80

Page 1